Laura Medve

Laura Medve

Auto-generated profile, based on publicly available information

Laura Medve

Univ. Lille, Inserm, Institut Pasteur de Lille, U1177, Drugs and Molecules for Living Systems 3 rue du Pr Laguesse 59000 Lille France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2019 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
LMLaura Medve
Laura Medve
SASilvia Achilli
Silvia Achilli
JGJoan Guzman‐Caldentey
Joan Guzman‐Caldentey
MTMichel Thépaut
Michel Thépaut
LSLuca Senaldi
Luca Senaldi
FFFranck Fieschi
Franck Fieschi
Chemical modification of pseudo‐dimannoside ligands guided by fragment‐based design allowed for the exploitation of an ammonium‐binding region in the vicinity of the mannose‐binding site of DC‐SIGN, leading to the synthesis of a glycomimetic antagonist (compound 16) of unprecedented affinity and selectivity against the related lectin langerin. Here, the computational design of pseudo‐dimannoside derivatives as DC‐SIGN ligands, their synthesis, their evaluation as DC‐SIGN selective antagonists, the biophysical characterization of the DC‐SIGN/16 complex, and the structural basis for the ligand activity are presented. On the way to the characterization of this ligand, an unusual bridging interaction within the crystals shed light on the plasticity and potential secondary binding sites within the DC‐SIGN carbohydrate recognition domain.

19 August 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
VCVirgyl Camberlein
Virgyl Camberlein
CFCharlotte Fléau
Charlotte Fléau
PSPierre Sierocki
Pierre Sierocki
LLLenong Li
Lenong Li
RGRonan Gealageas
Ronan Gealageas
RDRebecca Deprez-Poulain
Rebecca Deprez-Poulain
Endoplasmic reticulum aminopeptidase 2 (ERAP2) is a key enzyme involved in the trimming of antigenic peptides presented by Major Histocompatibility Complex class I. It is a target of growing interest for the treatment of autoimmune diseases and in cancer immunotherapy. However, the discovery of potent and selective ERAP2 inhibitors is highly challenging. Herein, we have used kinetic target‐guided synthesis (KTGS) to identify such inhibitors. Co‐crystallization experiments revealed the binding mode of three different inhibitors with increasing potency and selectivity over related enzymes. Selected analogues engage ERAP2 in cells and inhibit antigen presentation in a cellular context. 4 d (BDM88951) displays favorable in vitro ADME properties and in vivo exposure. In summary, KTGS allowed the discovery of the first nanomolar and selective highly promising ERAP2 inhibitors that pave the way of the exploration of the biological roles of this enzyme and provide lead compounds for drug discovery efforts.

3 September 2018 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
LMLaura Medve
Laura Medve
SASilvia Achilli
Silvia Achilli
SSSonia Serna
Sonia Serna
FZFabio Zuccotto
Fabio Zuccotto
NVNorbert Varga
Norbert Varga
ABAnna Bernardi
Anna Bernardi
A library of mannose‐ and fucose‐based glycomimetics was synthesized and screened in a microarray format against a set of C‐type lectin receptors (CLRs) that included DC‐SIGN, DC‐SIGNR, langerin, and dectin‐2. Glycomimetic ligands able to interact with dectin‐2 were identified for the first time. Comparative analysis of binding profiles allowed their selectivity against other CLRs to be probed.

19 August 2022 in Angewandte Chemie
Verified
Journal Article
Open access
VCVirgyl Camberlein
Virgyl Camberlein
CFCharlotte Fléau
Charlotte Fléau
PSPierre Sierocki
Pierre Sierocki
LLLenong Li
Lenong Li
RGRonan Gealageas
Ronan Gealageas
RDRebecca Deprez-Poulain
Rebecca Deprez-Poulain
Endoplasmic reticulum aminopeptidase 2 (ERAP2) is a key enzyme involved in the trimming of antigenic peptides presented by Major Histocompatibility Complex class I. It is a target of growing interest for the treatment of autoimmune diseases and in cancer immunotherapy. However, the discovery of potent and selective ERAP2 inhibitors is highly challenging. Herein, we have used kinetic target‐guided synthesis (KTGS) to identify such inhibitors. Co‐crystallization experiments revealed the binding mode of three different inhibitors with increasing potency and selectivity over related enzymes. Selected analogues engage ERAP2 in cells and inhibit antigen presentation in a cellular context. 4 d (BDM88951) displays favorable in vitro ADME properties and in vivo exposure. In summary, KTGS allowed the discovery of the first nanomolar and selective highly promising ERAP2 inhibitors that pave the way of the exploration of the biological roles of this enzyme and provide lead compounds for drug discovery efforts.